GRAIL (NASDAQ:GRAL) Releases Quarterly Earnings Results

GRAIL (NASDAQ:GRAL) issued its quarterly earnings results on Wednesday. The company reported ($2.21) EPS for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24, FiscalAI reports. The business had revenue of $37.53 million during the quarter, compared to the consensus estimate of $44.21 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%.

Here are the key takeaways from GRAIL’s conference call:

• Galleri received a favorable FDA advisory committee vote, with GRAIL expecting an FDA decision by early Q1 2027. The company said discussions with the FDA are active, including label negotiations, but no decision date has been provided.
• GRAIL highlighted clinical results showing Galleri detected 4–6.5 times more cancers when added to standard screening, with nearly half of detected cancers at stages 1 or 2; it also reported a 20% reduction in stage 4 diagnoses for a prespecified group of 12 cancers. However, the NHS-Galleri trial did not show a reduction in the combined incidence of stage 3 and 4 cancers.
• Test volume rose 24% year over year in Q3 and 36% in the first nine months, with the company citing provider activation and reactivation. GRAIL is expanding sales, health-system integrations and marketing, while using promotional pricing to encourage demand ahead of a potential FDA decision.
• Q3 revenue increased just 4% to $37.5 million despite 24% volume growth, as lower average selling prices weighed on results. Adjusted gross margin fell to 42% from 55%, adjusted EBITDA loss widened 29%, and GRAIL lowered full-year Galleri sales revenue growth guidance to 17%–21%; the Illumina royalty is also expected to resume in late December.
• GRAIL ended the quarter with $788.7 million in cash and said its cash position provides runway into 2029; its 2026 cash-burn guidance of no more than $300 million was unchanged.

GRAIL Price Performance

Shares of GRAL traded up $4.22 during mid-day trading on Wednesday, hitting $143.66. The company had a trading volume of 755,261 shares, compared to its average volume of 924,130. The business’s 50-day simple moving average is $115.58 and its 200-day simple moving average is $79.12. GRAIL has a 1-year low of $41.50 and a 1-year high of $166.48.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GRAL. Canaccord Genuity Group upped their price objective on shares of GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Robert W. Baird lifted their target price on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 22nd. Mizuho lifted their target price on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Finally, UBS Group increased their price target on GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $119.80.

Insider Buying and Selling

In other GRAIL news, CFO Aaron Freidin sold 23,619 shares of GRAIL stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $3,457,585.41. Following the transaction, the chief financial officer owned 225,364 shares in the company, valued at $32,991,035.96. This trade represents a 9.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua J. Ofman sold 61,452 shares of GRAIL stock in a transaction on Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the transaction, the chief executive officer owned 362,271 shares in the company, valued at approximately $35,408,367.54. This trade represents a 14.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 129,944 shares of company stock valued at $14,832,805. Insiders own 1.83% of the company’s stock.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.